Show simple item record

dc.contributor.authorWallace, Jan
dc.contributor.authorWoda, Bruce A.
dc.contributor.authorPihan, German A.
dc.date2022-08-11T08:09:31.000
dc.date.accessioned2022-08-23T16:34:14Z
dc.date.available2022-08-23T16:34:14Z
dc.date.issued2005-02-01
dc.date.submitted2009-03-10
dc.identifier.citationJ Mol Diagn. 2005 Feb;7(1):72-80.
dc.identifier.issn1525-1578 (Print)
dc.identifier.pmid15681477
dc.identifier.urihttp://hdl.handle.net/20.500.14038/38285
dc.description.abstractHuman papillomavirus (HPV) is the worldwide cause of carcinoma of the uterine cervix, a cancer that is the second most common neoplasm in women, resulting in nearly 250,000 deaths a year. The magnitude of the risk of cancer after HPV infection, however, is virus type-specific. Over 40 HPV types can infect the genital tract. Comprehensive, high-throughput typing assays for HPV, however, are not currently available. Blending multiplex PCR and multiplex hybridization using spectrally addressable liquid bead microarrays we have developed a high-throughput, fast, single-tube-typing assay capable of simultaneously typing 45 HPV. The overall incidence of HPV in 429 women tested using this new assay was 72.2% for those with squamous intraepithelial lesions, 51.5% for those with atypical squamous cells of undetermined significance and 15.4% for women with normal cytology, respectively. This compared well with the incidence of HPV detected by a parallel non-typing generic high-risk assay. The new assay detected a wide spectrum of HPV types and a high incidence of mixed infections. We believe our assay may find widespread applications in areas requiring virus type-specific information, such as in epidemiological studies, cancer screening programs, monitoring therapeutic interventions, and evaluating the efficacy of HPV vaccine trials.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=15681477&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC1867512/?tool=pubmed
dc.subjectDNA, Viral
dc.subjectFemale
dc.subjectGenotype
dc.subjectHumans
dc.subjectMicrospheres
dc.subjectOligonucleotide Array Sequence Analysis
dc.subjectPapillomaviridae
dc.subjectPapillomavirus Infections
dc.subjectPolymerase Chain Reaction
dc.subjectUterine Cervical Neoplasms
dc.subjectLife Sciences
dc.subjectMedicine and Health Sciences
dc.titleFacile, comprehensive, high-throughput genotyping of human genital papillomaviruses using spectrally addressable liquid bead microarrays
dc.typeJournal Article
dc.source.journaltitleThe Journal of molecular diagnostics : JMD
dc.source.volume7
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/1157
dc.identifier.contextkey770135
html.description.abstract<p>Human papillomavirus (HPV) is the worldwide cause of carcinoma of the uterine cervix, a cancer that is the second most common neoplasm in women, resulting in nearly 250,000 deaths a year. The magnitude of the risk of cancer after HPV infection, however, is virus type-specific. Over 40 HPV types can infect the genital tract. Comprehensive, high-throughput typing assays for HPV, however, are not currently available. Blending multiplex PCR and multiplex hybridization using spectrally addressable liquid bead microarrays we have developed a high-throughput, fast, single-tube-typing assay capable of simultaneously typing 45 HPV. The overall incidence of HPV in 429 women tested using this new assay was 72.2% for those with squamous intraepithelial lesions, 51.5% for those with atypical squamous cells of undetermined significance and 15.4% for women with normal cytology, respectively. This compared well with the incidence of HPV detected by a parallel non-typing generic high-risk assay. The new assay detected a wide spectrum of HPV types and a high incidence of mixed infections. We believe our assay may find widespread applications in areas requiring virus type-specific information, such as in epidemiological studies, cancer screening programs, monitoring therapeutic interventions, and evaluating the efficacy of HPV vaccine trials.</p>
dc.identifier.submissionpathoapubs/1157
dc.contributor.departmentDepartment of Pathology
dc.contributor.departmentLaboratory of Diagnostic Molecular Oncology
dc.source.pages72-80


This item appears in the following Collection(s)

Show simple item record